TREATMENT OF COGNITIVE IMPAIRMENT OF HUNTER SYNDROME BY INTRATHECAL DELIVERY OF IDURONATE-2-SULFATASE
Patent №
US 9,682,129
Granted
2017-06-20
Filed 2014
Owner
SHIRE HUMAN GENETIC THERAPIES, INC.
Lab
—
AI components
1
hardware
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
14367864
The present invention provides a method of treating cognitive impairment of Hunter syndrome. Among other things, the present invention provides a method comprising a step of administering intrathecally to a subject in need of treatment a recombinant iduronate-2-sulfatase (I2S) enzyme at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce declining of one or more cognitive, adaptive, motor, and/or executive functions relative to a control.
AI classification
Ownership
SHIRE HUMAN GENETIC THERAPIES, INC.
assignment · 299480947
Assignors
BARBIER, ANN, MCCAULEY, THOMAS, RICHARD, III, CHARLES W., BARBIER, ANN, MCCAULEY, THOMAS, RICHARD, CHARLES W., III
On an employer assignment, the assignors are typically the inventors.